Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Riber Earnings Release 2011

Apr 12, 2011

1629_iss_2011-04-12_4a2151fd-b0e9-4b33-bcc3-a9a3d45b9e75.pdf

Earnings Release

Open in viewer

Opens in your device viewer

Bezons, April 12th, 2011; 5:45 pm

2011 first-quarter revenue growth of 98% Order book up 134% over one year

Bezons, April 12th, 2011 – 5:45 pm – RIBER, the global leader for molecular beam epitaxy (MBE), recorded €5.7 million in revenues for the first quarter of 2011, up 98% in relation to the first quarter of 2010, with its order book climbing 134% compared with last year to €21.3 million.

At March 31st (€'000,000) 2011 2010 Change
Systems 2.1 1.1 +92%
Cells and sources 2.6 0.3 x9
Services and accessories 1.0 1.5 -34%
Total reported revenues 5.7 2.9 +98%
Systems order book 14.0 6.9 +103%
Cells and sources order book 5.0 0.2 x25
Services and accessories order book 2.3 2.0 +15%
Total order book 21.3 9.1 +134%

Growth in business is being driven by the development of systems sales, with two machines delivered during the first quarter.

This is combined with the increase in sales of evaporation sources and cells, multiplied by nine compared with the same period in 2010. This change reflects ongoing move to diversify RIBER's activities on the strongly growing OLED (Organic LED) and thin-layer solar panel (CIGS technology) markets.

Sales of services and accessories are down temporarily compared with the high level seen in the first quarter of 2010.

The positive evolution of revenues also results from Riber's policy aiming to evenly spread production throughout the year.

Strong outlook for 2011

The order book at the end of March 2011 came to €21.3 million, 134% higher than the same period in 2010. It consists of six research systems and four production systems, with the company receiving an order for a new production machine in March. Out of these 10 machines in the order book, only one system is not scheduled to be delivered during the year. In addition, the book includes major effusion cell orders in the OLED sector.

These good trends confirm the relevance of RIBER's strategy, based on:

  • Continuing to further strengthen its leadership on the market for molecular beam epitaxy machines;
  • Capitalizing on the installed base and growing sales of epitaxy equipment, spare parts and accessories, as well as the corresponding services;
  • Releasing a range of high value-added equipment and services on the market for strong-growth application fields (thinlayer solar cells, OLED lighting and screens, etc.).

As each year, RIBER will be releasing its revenue forecasts at the end of the first half of 2011.

Next date: General Meeting on Thursday May 26th, 2011

About RIBER:

Riber designs and produces molecular beam epitaxy (MBE) systems as well as evaporation sources and cells for the semiconductor industry. This high-technology equipment is essential for the manufacturing of compound semiconductor materials and new materials that are used in numerous consumer applications, such as new information technologies, OLED flat screens and new generation solar cells.

Riber is listed on Euronext Paris Compartment "C" and is part of the CAC IT index.

ISIN code: FR0000075954 Reuters code: RIBE.PA Bloomberg code: RIB: FP

Riber has been innovation certified by OSEO, the dedicated French innovation agency, enabling it to qualify for French innovation mutual funds (FCPI).

RIBER CALYPTUS
Olivier Handschumacher Cyril Combe
tel: +33 1 39 96 65 00 tel: +33 1 53 65 68 68
[email protected] [email protected]